Rimonabant: The first therapeutically relevant cannabinoid antagonist

This publication has 57 references indexed in Scilit:

• Nicotine-Associated Cues Maintain Nicotine-Seeking Behavior in Rats Several Weeks after Nicotine Withdrawal: Reversal by the Cannabinoid (CB1) Receptor Antagonist, Rimonabant (SR141716)
  Neuropsychopharmacology, 2004
• Cannabinoids Enhance Subsecond Dopamine Release in the Nucleus Accumbens of Awake Rats
  Journal of Neuroscience, 2004
• The Cannabinoid CB1 Receptor Antagonist SR141716 Increases Acrp30 mRNA Expression in Adipose Tissue of Obese fa/fa Rats and in Cultured Adipocyte Cells
  Molecular Pharmacology, 2003
• SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats
  Behavioural Pharmacology, 2002
• Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system
  European Journal of Pharmacology, 2001
• Appetite suppression and weight loss after the cannabinoid antagonist SR 141716
  Life Sciences, 1998
• REDUCTION OF VOLUNTARY ETHANOL INTAKE IN ETHANOL-PREFERRING sP RATS BY THE CANNABINOID ANTAGONIST SR-141716
  Alcohol and Alcoholism, 1998
• Involvement of central cannabinoid (CB 1 ) receptors in the establishment of place conditioning in rats
  Psychopharmacology, 1998
• A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1
  Journal of Biological Chemistry, 1997
• Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors
  Psychopharmacology, 1997